Osteoporosis screening, what the guidelines actually say

Osteoporosis screening looks like a simple age-gated recommendation from a distance, women past a certain age get a bone scan, but the 2025 update the Task Force finalized makes clear that a meaningful part of the eligible population is defined by risk, not by a birthday, and that the evidence for screening men still is not there.

What this screening is and what it looks for

Osteoporosis is a condition in which bones lose density and become more likely to fracture, often without symptoms until a fracture occurs. Screening measures bone mineral density, most commonly with dual-energy X-ray absorptiometry (DXA), a low-radiation scan usually of the hip and spine. The USPSTF frames the goal as preventing osteoporotic fractures, particularly hip fractures, which carry a substantial risk of disability and death in older adults, rather than diagnosing bone loss for its own sake.

Who and when, per the USPSTF

The 2025 final recommendation sets out three separate conclusions, and only one of them is a simple age cutoff:

• Women 65 and older: Grade B. The Task Force recommends screening for osteoporosis in this group, concluding with moderate certainty that it has a moderate net benefit. This is the age-based population this page’s facts panel and underlying dataset reflect.
• Postmenopausal women younger than 65 at increased risk of osteoporotic fracture: Grade B. This is a separate recommendation with the same letter grade, but it is risk-based rather than age-based: the Task Force recommends a two-step approach, first using a clinical risk assessment tool, the Task Force names FRAX, the Osteoporosis Self-Assessment Tool (OST), and the Osteoporosis Risk Assessment Instrument (ORAI) as options, to identify increased risk (accounting for factors such as low body weight, a parent’s history of hip fracture, smoking, or heavy alcohol use), and screening with DXA only for those the tool flags. A postmenopausal woman under 65 who has not been risk-assessed is not automatically covered by this Grade B the way a woman 65 or older is covered by age alone.
• Men of any age: Grade I. The Task Force concludes that current evidence is insufficient to assess the balance of benefits and harms of screening men for osteoporosis, and does not recommend for or against it.

Because a single age-and-sex field cannot represent an age-based recommendation and a risk-based recommendation with the same grade honestly, this tracker’s structured data carries the women-65-and-older band as its one graded row for this screening; the younger, risk-based population is real Task Force guidance but is not reducible to a simple age band the way the 65-and-older group is. These conclusions describe guideline eligibility and how it is determined, not an instruction that any particular person should be screened, or skipped, on a particular basis. Whether a risk assessment tool suggests earlier screening for you, or whether the insufficient-evidence conclusion for men should factor into your own decision, is a conversation for a clinician.

The evidence and its grade

The moderate-certainty, moderate-benefit conclusion for women 65 and older rests on trial and cohort evidence that DXA screening, followed by treatment for those found to have osteoporosis, reduces fracture risk, weighed against modest harms from the scan itself and from treating people who would not have fractured regardless. For postmenopausal women younger than 65, fracture risk varies enormously by individual risk factors rather than tracking age closely, which is why the Task Force built a two-step, tool-based pathway instead of picking a single younger age cutoff the way it does for the 65-and-older group; the underlying evidence supports screening people at elevated risk, not an unconditional younger population. For men, the Task Force is explicit that the evidence gap is not a finding of no benefit; it is an absence of sufficient trial data in men to support a graded conclusion in either direction, a genuinely different statement from “screening does not work in men.”

Where the guidance differs

The USPSTF’s Grade I for men is the sharpest point of disagreement with other bodies in this space. The Bone Health and Osteoporosis Foundation’s Clinician’s Guide, most recently updated in 2022, recommends bone density testing in men aged 70 and older, and in men aged 50 to 69 who have clinical risk factors for fracture, a specific, graded position where the USPSTF states the evidence is insufficient to take one. Neither body has access to different raw data than the other; they differ on how much evidence is required before recommending a screening test to a population, and the Foundation, whose guide draws more heavily on expert consensus and risk-factor modeling alongside the trial evidence, reaches a more permissive threshold than the Task Force’s own bar for a graded recommendation. That is a real, documented difference in judgment, not one side simply being wrong.

Questions to ask your clinician

Framed as questions to bring to a visit, not as steps to take on your own:

• I am a woman 65 or older; does the Grade B recommendation mean I should have already been screened, and if not, what is the next step?
• I am a postmenopausal woman younger than 65; has anyone assessed my fracture risk with a tool like FRAX, OST, or ORAI, and does that assessment suggest earlier screening for me?
• I am a man; how should I weigh the USPSTF’s insufficient-evidence conclusion against a guideline like the Bone Health and Osteoporosis Foundation’s, which does recommend screening for men my age or risk profile?
• What specific risk factors of mine, body weight, family history, smoking, alcohol use, or a medication I take, are relevant to whether I should be screened earlier or more closely than the general recommendation suggests?
• If a DXA scan shows low bone density, what happens next, and how is that different from a diagnosis of osteoporosis itself?

You can compare this profile against the full Guideline Tracker, read the sibling profile for abdominal aortic aneurysm screening, or see how everyday choices fit alongside screening in the big levers.